Linde LIN
- Market cap
- $234.6B
- PE
- 32.9×
- 10y median 34.4×
- Forward PE
- 27.2×
- 10y median 26.3×
- Price to sales
- 6.6×
- EV/EBIT
- 28.2×
- Revenue, 12 months
- $35.4B
- +7% on a year ago
- Net margin
- 20.4%
- Free cash flow yield
- 2.1%
Linde trades at 32.9× trailing earnings, cheaper than 69% of the last ten years. Revenue was $35.4B over the last twelve months, up 7% on a year earlier with a 20% net margin.
Charts
Financials
| Income statement | Q3 FY23 | Q4 FY23 | Q1 FY24 | Q2 FY24 | Q3 FY24 | Q4 FY24 | Q1 FY25 | Q2 FY25 | Q3 FY25 | Q4 FY25 | Q1 FY26 | Q2 FY26 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| $8.2B−7% | $8.3B+5% | $8.1B−1% | $8.3B+1% | $8.4B+3% | $8.3B−0% | $8.1B+0% | $8.5B+3% | $8.6B+3% | $8.8B+6% | $8.8B+8% | $9.3B+9% | |
| Cost of revenue | $4.3B−18% | $4.4B+0% | $4.2B−5% | $4.3B−2% | $4.4B+1% | $4.3B−3% | $4.2B−1% | $4.3B+1% | $4.4B+1% | $4.5B+5% | $4.5B+9% | $4.9B+13% |
| Gross profit | $3.8B+9% | $3.9B+12% | $3.9B+3% | $4B+3% | $4B+4% | $4B+2% | $4B+2% | $4.2B+4% | $4.2B+6% | $4.2B+6% | $4.3B+8% | $4.4B+6% |
| R&D | $36M+3% | $39M+8% | $38M+6% | $36M+3% | $37M+3% | $39M+0% | $38M+0% | $38M+6% | $36M−3% | $35M−10% | $38M+0% | $37M−3% |
| SG&A | $808M+5% | $832M+9% | $860M+5% | $840M+1% | $823M+2% | $814M−2% | $786M−9% | $870M+4% | $897M+9% | $880M+8% | $893M+14% | $891M+2% |
| $2.1B+27% | $2B+20% | $2.1B+8% | $2.2B+9% | $2.1B+2% | $2.3B+12% | $2.2B+4% | $2.4B+8% | $2.4B+14% | $2B−11% | $2.4B+12% | $2.6B+9% | |
| Interest expense | $40M+122% | $351M+43% | $65M+76% | $70M+35% | $68M+70% | $53M−85% | $60M−8% | $67M−4% | $64M−6% | $64M+21% | $62M+3% | $61M−9% |
| Pre-tax income | $2B+24% | $2B+17% | $2.1B+7% | $2.2B+8% | $2.1B+1% | $2.3B+13% | $2.2B+5% | $2.3B+9% | $2.4B+14% | $2B−11% | $2.4B+12% | $2.5B+9% |
| $487M+25% | $459M+18% | $463M+8% | $508M+16% | $498M+2% | $533M+16% | $511M+10% | $573M+13% | $424M−15% | $481M−10% | $571M+12% | $610M+7% | |
| Net income | $1.6B+23% | $1.5B+16% | $1.6B+7% | $1.7B+6% | $1.6B−1% | $1.7B+12% | $1.7B+3% | $1.8B+6% | $1.9B+25% | $1.5B−11% | $1.9B+11% | $1.9B+9% |
| $3.19+26% | $3.16+18% | $3.35+10% | $3.44+8% | $3.22+1% | $3.60+14% | $3.51+5% | $3.73+8% | $4.09+27% | $3.26−9% | $3.98+13% | $4.15+11% | |
| 491.1M−2% | 488.2M−2% | 485.6M−2% | 483.2M−2% | 480.9M−2% | 478.8M−2% | 476.3M−2% | 473.6M−2% | 471.5M−2% | 468.3M−2% | 466.3M−2% | 464.5M−2% |
Gross profit: 74 periods, Q1 FY08 to Q2 FY26: not printed by the filing, worked out from its own lines.
Net income: 5 periods, Q4 FY09 to Q4 FY23: printed in the fourth-quarter results release.
EPS, diluted: 5 periods, Q4 FY08 to Q4 FY19: quarter's net income to common over its shares, to the cent. 7 periods, Q4 FY09 to Q4 FY25: printed in the fourth-quarter results release.
Diluted shares: 3 periods, Q4 FY08 to Q4 FY25: share-days: the 12-month average less the 9-month, weighted by days. 5 periods, Q4 FY09 to Q4 FY23: printed in the fourth-quarter results release.
From each company's 10-Q and 10-K filings, the newest version of each figure. Quarters are as filed (a fourth quarter is the year less its first nine months), fiscal years as the 10-K prints them, restated where a later 10-K restated them, and balance sheet lines as of the period's end. A quarter whose 10-Q isn't filed yet is from the company's results release. Growth is on the same period a year earlier. A dash is a period with no figure for the line: the filing doesn't print it, or it hasn't been read yet.
Estimates
Next earnings report: .
| Quarter | Revenue | Range | EPS | Range | Analysts |
|---|---|---|---|---|---|
| Q3 FY26 | $9.2B | $8.9B to $9.4B | $4.52 | $4.50 to $4.55 | 14 |
| Q4 FY26 | $9.2B | $9.1B to $9.3B | $4.53 | $4.47 to $4.59 | 4 |
| Q1 FY27 | $9.2B | $9B to $9.4B | $4.70 | $4.56 to $4.82 | 1 |
| Q2 FY27 | $9.7B | $9.5B to $9.9B | $4.94 | $4.79 to $5.06 | 1 |
| Q3 FY27 | $9.6B | $9.4B to $9.8B | $4.96 | $4.81 to $5.09 | 1 |
| Q4 FY27 | $9.7B | $9.5B to $9.9B | $4.97 | $4.82 to $5.10 | 1 |
| Q1 FY28 | $9.8B | $9.5B to $9.9B | $5.14 | $4.98 to $5.26 | 2 |
| Q2 FY28 | $10.3B | $10B to $10.4B | $5.42 | $5.25 to $5.55 | 2 |
Peers
Companies in Chemicals - Specialty nearest Linde's size, closest first.
| Company | Market cap | PE | Its 10y median PE | Fwd PE | P/S | Revenue growth | Net margin |
|---|---|---|---|---|---|---|---|
| LINLinde | $234.6B | 32.9× | 34.4× | 27.2× | 6.6× | +7% | 20.4% |
| SHWSherwin-Williams | $81.8B | 31.1× | 33.3× | 26.3× | 3.4× | +6% | 11.0% |
| ECLEcolab | $80.9B | 38.7× | 37.3× | 33.5× | 4.8× | +7% | 12.6% |
| APDAir Products and Chemicals | $68.4B | n/m | 28.1× | 21.6× | 5.4× | +5% | −0.4% |
| PPGPPG Industries | $24.6B | 15.8× | 24.0× | 13.4× | 1.5× | +5% | 9.6% |
| IFFInternational Flavors & Fragrances | $24B | 82.6× | 35.5× | 27.3× | 2.4× | −5% | 2.9% |
| Peer median | $68.4B | 34.9× | 33.3× | 26.3× | 3.4× | +5% | 9.6% |
Investors who own it
Investors we follow who held Linde at the end of Jun 30, 2026, from their 13F filings.
- Stephen MandelLone Pine Capital4.9% of portfolionew
- John ArmitageEgerton Capital1.5% of portfoliotrimmed
- Tom GaynerMarkel Group0.9% of portfolioadded
- Dan SundheimD1 Capital Partners0.5% of portfolionew
- Stanley DruckenmillerDuquesne Family Office0.5% of portfolio
- Ron BaronBaron Capital0.0% of portfolionew
More on Linde
Each number over time
- PE ratio
- Forward PE
- Price to sales ratio
- EV/EBIT
- Price to free cash flow
- Price to book ratio
- Dividend yield
- Market cap
- Revenue
- EPS
- Free cash flow
- Profit margin
- Shares outstanding
Where it ranks
- #1of 27Specialty chemicals stocks with the highest profit margins
- #8of 29Specialty chemicals stocks with the fastest revenue growth
- #4of 12Specialty chemicals stocks with the fastest earnings growth
- #10of 22Materials stocks with the highest dividend yields
- #8of 13Specialty chemicals stocks cheapest against their own PE history
Its groups
About
- Industry
- Chemicals - Specialty
- Sector
- Basic Materials
Valuation data, not investment advice. Prices as of .